Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Hormone Therapy and Ovarian Cancer

Hormone Therapy and Ovarian Cancer ORIGINAL CONTRIBUTION Lina Steinrud Mørch, MSc Context Studies have suggested an increased risk of ovarian cancer among women Ellen Løkkegaard, MD, PhD taking postmenopausal hormone therapy. Data are sparse on the differential effects of formulations, regimens, and routes of administration. Anne Helms Andreasen, MSc Objective To assess risk of ovarian cancer in perimenopausal and postmenopausal Susanne Krüger-Kjær, MD, DrMSci women receiving different hormone therapies. Øjvind Lidegaard, MD, DrMSci Design and Setting Nationwide prospective cohort study including all Danish women aged 50 through 79 years from 1995 through 2005 through individual linkage to Dan- RIMARY PREVENTION OF OVAR- ish national registers. Redeemed prescription data from the National Register of Me- ian cancer is challenging be- dicinal Product Statistics provided individually updated exposure information. The Na- cause little is known about its tional Cancer Register and Pathology Register provided ovarian cancer incidence data. Petiology. A review and meta- Information on confounding factors and effect modifiers was from other national reg- analysis of data published between 1966 isters. Poisson regression analyses with 5-year age bands included hormone expo- sures as time-dependent covariates. and 2006 concluded that current use of postmenopausal hormone therapy (HT) Participants A total of 909 946 women without hormone-sensitive http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Loading next page...
 
/lp/american-medical-association/hormone-therapy-and-ovarian-cancer-AKHQ4I2dP3
Publisher
American Medical Association
Copyright
Copyright 2009 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2009.1052
pmid
19602689
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL CONTRIBUTION Lina Steinrud Mørch, MSc Context Studies have suggested an increased risk of ovarian cancer among women Ellen Løkkegaard, MD, PhD taking postmenopausal hormone therapy. Data are sparse on the differential effects of formulations, regimens, and routes of administration. Anne Helms Andreasen, MSc Objective To assess risk of ovarian cancer in perimenopausal and postmenopausal Susanne Krüger-Kjær, MD, DrMSci women receiving different hormone therapies. Øjvind Lidegaard, MD, DrMSci Design and Setting Nationwide prospective cohort study including all Danish women aged 50 through 79 years from 1995 through 2005 through individual linkage to Dan- RIMARY PREVENTION OF OVAR- ish national registers. Redeemed prescription data from the National Register of Me- ian cancer is challenging be- dicinal Product Statistics provided individually updated exposure information. The Na- cause little is known about its tional Cancer Register and Pathology Register provided ovarian cancer incidence data. Petiology. A review and meta- Information on confounding factors and effect modifiers was from other national reg- analysis of data published between 1966 isters. Poisson regression analyses with 5-year age bands included hormone expo- sures as time-dependent covariates. and 2006 concluded that current use of postmenopausal hormone therapy (HT) Participants A total of 909 946 women without hormone-sensitive

Journal

JAMAAmerican Medical Association

Published: Jul 15, 2009

References